Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis

Author:

Carazo Sara,Billard Marie-Noëlle,Boutin Amélie,De Serres GastonORCID

Abstract

Abstract Background The objectives of this review were to evaluate the effect of age at administration of the first dose of a measles-containing vaccine (MCV1) on protection against measles and on antibody response after one- and two-dose measles vaccinations. Methods We conducted a systematic review of the PubMed/MEDLINE, Embase, Web of Science and Cochrane databases (1964–2017) to identify observational studies estimating vaccine effectiveness and/or measles attack rates by age at first vaccination as well as experimental studies comparing seroconversion by age at first vaccination. Random effect models were used to pool measles risk ratios (RR), measles odds ratios (OR) and seroconversion RR of MCV1 administered at < 9, 9–11 or ≥ 15 months compared with 12 or 12–14 months of age. Results We included 41 and 67 studies in the measles protection and immunogenicity analyses. Older age at MCV1, from 6 to ≥15 months, improved antibody response and measles protection among one-dose recipients. Pooled measles RR ranged from 3.56 (95%CI: 1.28, 9.88) for MCV1 at < 9 months to 0.48 (95%CI: 0.36, 0.63) for MCV1 at ≥15 months, both compared to 12–14 months. Pooled seroconversion RR ranged from 0.93 (95%CI: 0.90, 0.96) for MCV1 at 9–11 months to 1.03 (95%CI: 1.00, 1.06) for MCV1 at ≥15 months, both compared to 12 months. After a second dose, serological studies reported high seropositivity regardless of age at administration of MCV1 while epidemiological data based on few studies suggested lower protection with earlier age at MCV1. Conclusions Earlier age at MCV1 decreases measles protection and immunogenicity after one dose and might still have an impact on vaccine failures after two doses of measles vaccine. While two-dose vaccination coverage is most critical to interrupt measles transmission, older age at first vaccination may be necessary to keep the high level of population immunity needed to maintain it.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Reference148 articles.

1. Moss WJ, Griffin DE. Measles. Lancet. 2012;379:153–64.

2. World Health Organization. Global measles and rubella strategic plan. 2012–2020. 2012. http://apps.who.int/iris/bitstream/10665/44855/1/9789241503396_eng.pdf. Accessed 15 Apr 2014.

3. Chawla U, Benera SK, Bandyopadhyay S, Chaudhary BN, Gupta OP, Khallendra RK, Ramaswamy J, Khare S, Sharma RS, Dutta KK. Field evaluation of measles vaccine efficacy in new Seemapuri, Shahdara zone-Delhi during 1990. J Commun Disord. 1990;22:134–9.

4. Rivest P, Bedard L, Arruda H, Trudeau G, Remis RS. Risk factors for measles and vaccine efficacy during an epidemic in Montreal. Can J Public Health. 1995;86:86–90.

5. Murray M, Rasmussen Z. Measles outbreak in a northern Pakistani village: epidemiology and vaccine effectiveness. Am J Epidemiol. 2000;151:811–9.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3